Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study by Gunelli, R et al.
Activity of endovesical gemcitabine in BCG-refractory bladder
cancer patients: a translational study
R Gunelli
1, E Bercovich
1, O Nanni
2, M Ballardini
2, GL Frassineti
2, N Giovannini
2, M Fiori
1, E Pasquini
3, P Ulivi
2,
GL Pappagallo
4, R Silvestrini
1 and W Zoli*,2
1Department of Urology, Morgagni-Pierantoni Hospital, Forlı`, Italy;
2Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy;
3Department of Oncology, Cervesi Hospital, Cattolica (RN), Italy;
4Department of Oncology, PF Calvi Hospital, Noale, Italy
Intravesical gemcitabine (Gem) has shown promising activity against transitional cell carcinomas (TCC) of the bladder, with moderate
urinary toxicity and low systemic absorption. The present phase II study evaluated the activity of biweekly intravesical treatment with
Gem using a scheme directly derived from in vitro preclinical studies. Patients with Bacille Calmette-Gue ´rin (BCG) -refractory Ta G3,
T1 G1-3 TCC underwent transurethral bladder resection and then intravesical instillation with 2000mg Gem diluted in 50ml saline
solution on days 1 and 3 for 6 consecutive weeks. Thirty-eight (95%) of the 40 patients showed persistent negative post-treatment
cystoscopy and cytology 6 months after Gem treatment, while the remaining 2 patients relapsed at 5 and 6 months. At a median
follow-up of 28 months, recurrences had occurred in 14 patients. Among these, four had downstaged (T) disease, three had a lower
grade (G) lesion and three had a reduction in both T and G. Urinary and systemic toxicity was very low, with no alterations in
biochemical profiles. In conclusion, biweekly instillation of Gem proved active in BCG-refractory Ta G3, T1 G1-3 TCC. Our results
highlight the importance of preclinical studies using in vitro systems that adequately reproduce the conditions of intravesical clinical
treatment to define the best therapeutic schedule.
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Superficial transitional cell carcinomas (TCC) represent about two-
thirds of all bladder cancers at first presentation and are a
heterogeneous population of tumours that do not invade the
muscularis propria. The European Organization for Research and
Treatment of Cancer and the European Association of Urology
Guidelines have identified three risk categories of TCC (low,
intermediate and high) (Oosterlinck et al, 2006).
Complete endoscopic eradication followed or not by a single
intravesical instillation with various drugs is the standard therapy for
patients with low-risk tumours, while drug instillation and/or Bacille
Calmette-Gue ´rin (BCG) treatment is reserved for patients with
intermediate-risk tumours in an attempt to reduce or delay
recurrence and progression. For patients with high-risk tumours,
BCG is considered the most effective conservative treatment, and
radical cystectomy is the current option for cases refractory to this
immunological therapy (Sylvester et al, 2002; Oosterlinck et al, 2006).
No one drug has proven superior in terms of efficacy.
Mitomycin, epidoxorubicin and doxorubicin have all shown to
have beneficial effects, but the optimal instillation scheme remains
to be defined (Malmstrom et al, 1999; Malmstrom, 2000).
Similarly, the best treatment for patients who fail to respond to
adjuvant intravesical treatment needs further investigation, but
cytotoxic drugs could represent an interesting alternative to
standard BCG therapy. In this setting, Gemcitabine (Gem), a new
generation deoxycytidine analogue, given systemically as a single
agent (Lorusso et al, 1998) or in combination with cisplatin,
carboplatin or taxanes (Li et al, 2005; Von Der Maase et al, 2005),
has proven effective against metastatic bladder lesions, yielding
27–38% response rates in different studies. Furthermore, pharmaco-
kinetic studies carried out after intravesical instillation have shown
a very low systemic absorption of Gem, indicating this drug as an
ideal candidate for intravesical therapy (Cozzi et al, 1999; Laufer
et al, 2003).
The aim of this phase II study was to analyse the activity of the
Gem treatment scheme that proved to be the most effective in
in vitro cell cultures, a system that adequately reproduces the
conditions of intravesical clinical treatment. The study was
performed on patients refractory to BCG and submitted to
transurethral bladder resection (TURB). Secondary end points
were time to recurrence, progression and overall tolerability.
MATERIALS AND METHODS
In vitro studies
Cell cultures The study was performed on two established
bladder cancer cell lines: a commercial cell line (HT1376) with a
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s37-h doubling time (obtained from American Type Culture
Collection, Rockville, MD, USA) and a cell line (MCR) established
in the Biological Laboratory of the Department of Medical
Oncology in Forlı ` (Zoli et al, 2004), with a 48-h doubling time.
Cells were maintained as a monolayer in culture medium (DMEM)
supplemented with 10% FCS, 100IUml
 1 penicillin, 100mgml
 1
streptomycin and 2mML -glutamine and subcultured weekly. All
the experiments were performed during exponential cell growth.
Growth inhibition assay Cells were seeded in 96-well, flat-
bottomed microtitre plates at a density of 10000cellswell
 1.A t
18–24h after plating, 100ml of culture medium with or without
Gem (kindly supplied by Ely Lilly, Florence, Italy) were added to
each well. At the end of drug exposure, cells were fixed with 50%
trichloroacetic acid and stained with 0.4% sulphorhodamine B
(Sigma-Aldrich, St Louis, MO, USA), dissolved in 1% acetic acid
(100mlwell
 1), and washed with 1% acetic acid to remove
unbound stain. Protein-bound stain was solubilised with 100ml
of 10mM unbuffered Tris base, and cell density was determined
using a fluorescence plate reader (wavelength, 540 or 510nm). The
sulphorhodamine B assay was used according to the method of
Skehan et al (1990). Cells were exposed to Gem for one or two 1-h
periods, the latter spaced out by a 24- or 48-h culture in drug-free
medium (wash-out). Cells were treated with 1, 2 or 3mgml
 1 of
Gem, taking into account that the peak plasma level for the drug is
3.2mgml
 1 (Abbruzzese et al, 1991). Control samples were
processed in the same way as treated samples but in drug-free
medium. Samples were run in octuplet, and each experiment was
repeated three times.
Flow cytometry At various observation times, the medium was
removed and cells were detached from the flasks by trypsin,
washed twice with PBS and stained according to the methods
specified below. A FACS Vantage flow cytometer (Becton
Dickinson, San Diego, CA, USA), equipped with an argon laser
(488nm), was used. Data acquisition and analysis were performed
using CELLQuest Pro software (Becton Dickinson, San Diego, CA,
USA) and ModFit 2.0 (DNA Modelling System, Verity Software
House, Inc., Topsham, ME, USA). Samples were run in triplicate
and each experiment was repeated three times. Standard errors
were below 5%.
Cell cycle perturbations Briefly, samples of 2 10
5 cells were
exposed to a 0.1mgml
 1. concentration of Gem for 1h. Cell cycle
distribution was determined immediately after treatment and 24 or
48h after drug removal. Control samples were processed in the
same way as treated samples but in drug-free medium. At the end
of drug exposure, cells were harvested and stained in a solution
containing RNase (10Kunitsml
 1; Sigma-Aldrich), NP40 (0.01%;
Sigma-Aldrich) and propidium iodide (PI) (1mgml
 1; Sigma-
Aldrich). After 30–60min, samples were analysed and expressed
as fractions of cells in the different cell cycle phases. Samples were
run in triplicate and 10000 events were collected for each replica.
Data reported are the average of three experiments, with errors
under 5%.
Apoptosis
Annexin-V assay: After Gem exposure, cells were harvested,
washed once in PBS and incubated with 25mlml
 1 of Annexin
V-FITC in binding buffer (Bender MedSystems, Vienna, Austria)
for 15min at 371C in a humidified atmosphere in the dark. Cells
were then washed again in PBS and suspended in binding buffer.
Immediately before flow cytometry analysis, PI was added to a
final concentration of 5mgml
 1 to distinguish between total
apoptotic cells (Ann-Vþ and PI  or þ) and necrotic cells
(Ann-V– and PIþ). For each sample, 15000 events were recorded.
Data analysis: The efficacy of the two Gem exposures according
to the different treatment schedules was determined by the R Index
(RI) method (Romanelli et al, 1998). Although several methods
have been proposed to evaluate the interaction between drugs, as
critically analysed by Zoli et al. (2001), most of these are not
applicable to drugs with a low cytotoxic effect. We therefore used
Kern’s method (Kern et al, 1988), modified by Romanelli
(Romanelli et al, 1998), to overcome this problem. In brief, the
expected cell growth (Sexp), defined as the product of the cell
growth observed after exposure to drug A and that observed after
drug B, and the observed cell growth (Sobs) after the exposure to
the combination of A and B were used to construct an index (RI):
R¼Sexp/Sobs. An RI¼1 indicated an additive effect. RI values
higher or lower than 1 indicated synergistic and antagonistic
effects, respectively.
In vivo studies
Inclusion criteria Patients who had disease recurrence (Ta G3, T1
G1-3 TCC) within 6 months of one induction cycle and at least
three maintenance cycles of BCG, with no residual disease after
TURB, were consecutively enrolled onto this phase II study.
AgeX18 years and WHO performance status (PS) 0–1. Normal
upper urinary tract and bladder capacity4300ml were documen-
ted before recruitment with Uro-CT scan and ultrasonography,
respectively. Tumour stage was defined according to the 1997 TNM
system (Sobin and Wittekind, 1997) and grading was based on the
1999 WHO classification (Epstein et al, 1998).
Exclusion criteria Previous partial cystectomy, prior pelvic
irradiation and clinical evidence of other malignancies or
histologically confirmed carcinoma in situ.
Informed consent was obtained before treatment, and patients
were required to be accessible for follow-up. The study protocol
was approved by the Local Ethics Committee of the participating
centres.
Therapeutic and evaluation protocol Two weeks after TURB, the
bladder was completely emptied by catheterisation and endo-
vesical instillation was performed with 2000mg Gem diluted in
50ml saline solution, without pH adjustment. The drug was
maintained in the bladder for at least 1h and then spontaneously
eliminated. The instillation was repeated on days 1 and 3 for the
six consecutive weeks. No maintenance treatment was planned.
Patients were evaluated for response at the end of treatment and
those with negative cystoscopy and cytology underwent close
surveillance. Cytological analysis of voided urine and cystoscopy
were performed at 3-month intervals for the first year, and every
6 months thereafter. In the event of positive cystoscopy, the lesion
was submitted to histological examination. Patients with residual
disease discontinued treatment and the subsequent therapeutic
approach was defined at the discretion of each patient’s physician.
The pre-study clinical evaluation comprised medical history,
general physical examination, ECG, Uro-CT scan, chest X-ray and
haematological evaluation (including WBC-PLT count, electrolytes
and liver and kidney function), and ultrasonography evaluation of
bladder capacity. Information on the date of treatment adminis-
tration, drug doses and chemotherapy-induced side effects was
recorded.
Toxicity and complete blood count were evaluated according to
NCI Common Toxicity Criteria (version 2.0) on the first day of
each cycle of therapy. A clinical, haematological and biochemical
assessment for each patient was performed every third week and
repeated at the end of treatment.
Gem dose was reduced to 1400mg in the presence of grade 3
urgency or dysuria in association with grade 3–4 haematuria. The
dose reduction was maintained throughout the treatment and
instillation was stopped if toxicity persisted. Intravesical treatment
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swas discontinued if the patient developed febrile neutropaenia
(absolute neutrophil count o1000cellsml
 3 and tempera-
tureX381C), documented bacteraemia in the presence of neutro-
paenia, grade 3 or 4 neutropaenia/thrombocytopaenia, bilirubin
41.5 upper limit of normal or transaminase43 upper limit of
normal. Therapy was delayed by one week in the event of grade 3
bladder toxicity.
Statistical analysis
For the primary objective of the clinical study, that is, the
evaluation of Gem activity, sample size was determined using the
optimum Simon’s two-stage design (Simon, 1989). ‘Response’ was
defined as the lack of residual disease at 6 months, certified by
cytological and endoscopic examinations. Positive urinary cyto-
logy, new lesions (superficial or infiltrating), nodal involvement
and systemic diffusion were considered a ‘no-response’. The study
was sized to refuse ‘response’ rates of 40% (P0) and to provide a
significance level of 0.10 with a statistical power of 90% in
assessing the activity of the regimen as a 60% ‘response’ rate (P1).
The upper limit for first-stage drug rejection was 11 ‘responses’ in
the 28 assessable patients. The upper limit of second-stage
rejection was 20 ‘responses’ within a total of 41 assessable patients.
Event-free survival (EFS) was defined as the interval between the
date of the first endovesical instillation and the first unfavourable
event, superficial disease, progression to infiltrating disease or the
last visit. Event-free survival was estimated by the Kaplan–Meier
method. Ninety-five percent confidence intervals (95% CI) for
‘response’ and EFS estimates were calculated.
RESULTS
In vitro studies
A cytostatic dose-dependent effect was produced by Gem after all
treatment schemes. The effect induced by a 1-h exposure to Gem
significantly increased (Po0.05) after a 24- and 48-h culture in
drug-free medium (wash-out) at all tested concentrations. A
generally higher sensitivity of MCR than HT1376 cells was
observed (Figure 1). Moreover, the analysis of the types of
interaction between the two 1-h exposures to Gem showed an
antagonistic effect on cell growth when these were consecutive.
Conversely, an additive interaction in HT1376 and synergistic
activity in MCR were observed when the two exposures were
spaced out by a 24-h (RI¼1.5) or 48-h (RI¼1.6) wash-out.
Cell cycle perturbations and induction of apoptosis were
analysed in an attempt to find an explanation for the different
types of interaction. After a 1-h exposure to Gem, we observed a
statistically significant increase of cells in G0–G1 phases (67% in
treated vs 46% in untreated samples, Po0.05), together with a
similar decrease in both S (25% vs 40%, Po0.05) and G2–M (7.3%
vs 14%, Po0.05) phases. These perturbations were still present
24h after Gem removal and the block in G0–G1 phases recovered
only after 48h, after which S phase, the antimetabolite’s target, was
repopulated (Table 1).
Gem treatment induced apoptosis in about one-third of tumour
cells. More specifically, 25% of apoptotic cells were observed after
a 1-h exposure to Gem followed by a 72-h culture in drug-free
medium, increasing to 35% following the sequential treatment (1-h
Gem-48-h wash-out-1-h Gem-24-h wash-out). Conversely,
the percentage of necrotic cells never exceeded 5%.
In vivo studies
Forty-one consecutive patients were enrolled onto the study by the
Urology Department of Forlı ` and the Oncology Department of
Cattolica. Forty patients completed treatment and were evaluable
for clinical end points and one patient was lost to follow-up
immediately after registration. All but one of the patients were
males, and age ranged from 40 to 87 years (median 66 years).
About two-thirds presented a monofocal lesion, 90% had T1
tumours and more than 95% had G2-3 lesions (Table 2).
Activity
In accordance with a Simon’s two-step design, we continued
recruitment into the second step, having observed more than 11
1-h Gem 1-h Gem + 24-h washout 1-h Gem + 48-h washout
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Figure 1 Dose–response cytotoxicity of Gem in bladder cancer cell lines after different treatment schemes.
Table 1 Distribution of cells in the different cycle phases after exposure to Gem (1mgml
 1)
MCR HT1376
G0–G1 SG 2–M G0–G1 SG 2–M
Untreated cells 46.0±0.7 40.0±0.5 14.0±0.4 50.0±0.6 38.0±0.2 12.0±0.2
Gem (1h) 67.7*±1.5 25.0*±1.1 7.3*±1.1 70.0*±1.2 22.0*±1.4 8.0±0.8
Gem (1h)-wash-out (24h) 72.5*±1.7 20.5*±1.2 7.0*±1.3 71.8*±1.1 19.0*±1.1 9.2±0.4
Gem (1h)-wash-out (48h) 54.7±0.3 35.5±0.3 9.8±0.2 58.6±1.1 32.0±1.3 9.4±0.3
Data represent mean percentage values±s.d. *Po0.05.
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sresponses in the first 28 enrolled patients. On the basis of the
primary end point of the study, 38 of the 40 (95%) evaluable
patients (95% CI: 83.1–99.4%) obtained a ‘response’ with respect
to the minimum expected rate of 60%.
Specifically, a ‘response’ was observed in 21 of the 23 high-risk
tumour patients (91%; 95% CI: 72.0–98.9%) and in all 17
intermediate-risk patients. The probability of event-free survival
for the entire case series was around 80% at 1 year and 66% at 2.5
years (Figure 2). At a median follow-up of 28 months, superficial
recurrences had been observed in 14 patients. Among these, four
relapsed with downstaged (T) disease, three exhibited a lower
grade (G) lesion and three had a reduction in both T and G.
Finally, two monofocal lesions presented as multifocal at relapse,
while the inverse situation was observed in one patient. Only two
patients relapsed at 5 and 6 months and both subsequently
underwent cystectomy (Table 3).
Toxicity
Systemic toxicity was very low, with no evidence of alterations in
biochemical profiles. HyperthermiaX381C was observed in only
one patient and required a Gem dose reduction. Hyperthermia
o381C was observed in six cases and was well controlled by
antipyretics. According to NCI-CTC criteria, 10 cases of grade 1
and 27 cases of grade 2 dysuria (pollakiuria and/or stranguria with
or without urgency) were observed. Good control of symptoms was
obtained in these patients with the administration of anti-
cholinergic drugs. Grade 3 dysuria caused a delay in therapy in
only three patients and was resolved with anticholinergics. A
consequent reduction in Gem dose was required. Haematuria was
never observed.
31–79 52–84 52–84 60–89 70–95 89–100 93–100 95% CI
50 66 66 73 82 95 100 EFS (%)
2 8 14 22 30 37 40 No. pts at risk
36 30 24 18 12 6 0 Time (months)  
E
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Figure 2 Event-free survival and 95% CI curves.
Table 2 Patient and tumour characteristics
n %
Gender
Male 38 92.5
Female 2 5.0
Age (years)
o60 10 25.0
60–74 17 42.5
X75 13 32.5
Focality
Monofocal 25 62.5
Mulltifocal 15 37.5
Stage
Ta 4 10.0
T1 36 90.0
Grading
G1 2 5.0
G2 21 52.5
G3 17 42.5
PS (WHO)
0 36 90.0
1 4 10.0
Table 3 Variations in Gem-induced pathological characteristics in
relapsed patients
Focality T G
Patient
code
Time to
recurrence
(months) Pre Post Pre Post Pre Post
Treatment at
relapse
0 3 1 2 M M1132 C y stectomy (+CIS)
0 6 1 3 m M1122 TURB
0 7 3 1 M m1122 TURB
09 31 m m 1 a 3 2 TURB
1 6 1 0 M M1122 Cystectomy
19 6 m M 1 a 2 2 TURB
26 19 M M a a 2 1 TURB
29 19 m m a a 2 2 TURB
30 14 m m 1 a 3 1 TURB
32 8 m m a a 2 2 TURB
3 4 1 3 M M1122 TURB
37 8 M M 1 a 2 1 TURB
38 5 M M a a 3 2 TURB
3 9 1 1 m m1122 TURB
T¼tumour stage; G¼tumour grade; M¼multifocal lesion; m¼monofocal lesion;
CIS¼carcinoma in situ; TURB¼transurethral bladder resection.
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sDISCUSSION
Although the standard adjuvant treatment for superficial bladder
cancer at high-risk of recurrence is intravesical BCG, the role of
this therapy is somewhat controversial for intermediate-risk
tumours due to the high frequency of side effects and the
uncertain risk/benefit ratio. Moreover, there is still no recom-
mended standard therapy for patients relapsing after conventional
intravesical treatments. New treatment options are therefore
needed, and Gem represents a promising drug.
In a phase I study by Dalbagni et al (2002), patients with BCG-
refractory bladder carcinoma were treated with biweekly instilla-
tions of Gem at scalar doses up to 20mgml
 1 for 6 weeks. This
schedule produced a 50% complete remission rate, with acceptable
local and systemic toxicity. A lower toxicity was reported by Laufer
et al (2003) in a dose-finding and pharmacokinetic study using
weekly Gem instillations at scalar doses up to 40mgml
 1 for
6 weeks. At the maximum dose, the plasmatic level of Gem was low
and grade 2 dysuria was observed in only one patient.
In our clinical protocol, in which the Gem intravesical treatment
scheme was derived from preclinical studies designed to evaluate
the cytotoxic activity of different Gem schedules, all but one
patient concluded the planned treatment. Moreover, moderate
urinary toxicity and no haematological side effects were observed,
notwithstanding the biweekly instillations, each of 20mgml
 1 of
Gem, for 6 weeks.
With regard to Gem activity, some phase II studies (De
Berardinis et al, 2004; Gontero et al, 2004; Campodonico et al,
2005) assessed its ablative effect on a single marker lesion left in
the bladder after complete resection of all other lesions. In these
studies, Gem, administered weekly for 6 weeks, produced a
response rate of about 50% with a very low frequency of systemic
and local toxicity, which generally did not exceed grade I.
The activity of Gem has also been investigated in BCG-refractory
patients following either weekly or biweekly administration. In
Bartoletti et al’s (2005) study, Gem given once a week for 6 weeks
was associated with a 74% and 13% recurrence-free survival in
patients with intermediate- and high-risk lesions, respectively, at a
median follow up of 13.6 months. The usefulness of the
antimetabolite was also confirmed by Kohjimoto in a small series
of BCG-refractory patients following biweekly administration
(Kohjimoto et al, 2005).
In a recent phase II study, 30 BCG-refractory patients were treated
biweekly with 2000mg Gem diluted in 100ml saline solution for 3
weeks, with each course separated by 1 week’s rest (Dalbagni et al,
2006). The complete disappearance of all evidence of disease was
obtained in 50% of patients and 21% were recurrence-free at 1 year.
In the present study, following a biweekly Gem administration
for 6 weeks, 80 and 66% of patients were event-free at the 1- and
2.5-year follow up, respectively, with fairly similar rates in
intermediate- and high-risk tumour subgroups. It is also
noteworthy that at relapse, lesions were frequently downstaged
and only two patients required cystectomy.
These important therapeutic results, which could at least delay
the need for invasive cystectomy, were associated with very modest
toxicity, underlying the importance of the experimentally derived
scheme.
In conclusion, further clinical studies are now needed to verify
the efficacy of this Gem schedule in an adjuvant setting, and more
preclinical research is warranted to explore and identify the most
effective Gem-containing combinations to evaluate in randomised
phase II–III studies.
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